Biomarkers for diabetes complications: The results of several clinical studies

Journal of Medical Biochemistry

Volumn 30, Issue 3, 2011, Pages 207-212

  Aslan, Diler ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

biomarkers; clinical studies; diabetes

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL LABORATORY; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DEATH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISABILITY; DISEASE COURSE; GENOMICS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOBIOLOGY; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; LIPIDOMICS; METABOLOMICS; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROTEIN URINE LEVEL; PROTEOMICS; STANDARD; TRANSCRIPTOMICS; URINALYSIS; URINARY EXCRETION;

EID: 79959565415     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-011-0024-4     Document Type: Article

References (62)

1. International Diabetes Association. Global Burden: Prevalence and Projections, 2010 and 2030. IDF Dia betes Atlas. http://www.diabete satlas.org/content/dia betesand-impaired-glucose-tolerance (Accessed: March 2011).
2. International Diabetes Association. Morbidity and Mor ta -lity. IDF Diabetes Atlas. http://www.diabete satlas.org/content/diabetes-mortality (Accessed: March 2011).
3. International Diabetes Association. The Economic Impacts of Diabetes. IDF Diabetes Atlas. http://www.dia -betesatlas.org/content/economic-impacts- diabetes (Accessed: March 2011).
4. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year Diabetes Care 2005; 28 (9): 2130-5.
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54 (6): 1615-25. (Pubitemid 40770750)
6. Marshall S, Flyvbjerg A. Prevention and early detection of vas cular complications of diabetes. BMJ 2006; 333: 475-80. (Pubitemid 44343444)
7. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008; 79 (8 Suppl): 1527-34.
8. Lin J, Hu FB, Mantzoros C, Curhan GC. Lipid and inflam -matory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 2010; 53 (2): 263-7.
9. Kolberg JA, Jrgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, et al. Development of a type 2 dia -betes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 2009; 32 (7): 1207-12.
10. Beisswenger PJ. Glycation and biomarkers of vascular com plications of diabetes. Amino Acids 2010. Doi: 10.1007/s00726-010-0784-z.
11. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3 (2): 101-8.
12. Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011. doi:10.1016/j.semcdb.2011.02.015.
13. Takeuchi M, Takino J, Yamagishi S. Involvement of TAGERAGE system in the pathogenesis of diabetic retinopathy. J Ophthalmol 2010; 1-12. doi:10.1155/2010/170393.
14. Lam CS, Benzie IF, Choi SW, Chan LY, Yeung VT, Woo GC. Relationships among diabetic retinopathy, antio xidants, and glycemic control. Optom Vis Sci 2011 Feb; 88 (2): 251-6.
15. Vicentini J, Valentini J, Grotto D, Paniz C, Roehrs M, Brucker N, et al. Association among microalbuminuria and oxidative stress biomarkers in patients with type 2 diabetes. J Investig Med 2011: 1-6.
16. Sharma RK, Rogojina AT, Chalam KV. Multiplex immu -noassay analysis of biomarkers in clinically accessible quan tities of human aqueous humor. Mol Vis 2009; 15: 60-9.
17. Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 2010; 10 (1): 37-42.
18. Snell-Bergeon JK, Maahs DM, Ogden LG, Kinney GL, Hokanson JE, Schiffer E, et. al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and dia betic kidney disease. Diabetes Technol Ther 2009; 11 (1): 1-9.
19. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Dia -betes Metab Res Rev 2010 Mar; 26 (3): 150-71.
20. Scott EM, Carter AM, Findlay JB. The application of proteomics to diabetes. Diab Vasc Dis Res 2005 May; 2 (2): 54-60. (Pubitemid 40826996)
21. Sundsten T, Eberhardson M, Gransson M, Bergsten P. The use of proteomics in identifying differentially ex -pressed serum proteins in humans with type 2 diabetes. Proteome Sci 2006; 12; 4: 22.
22. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to deve -lopment of nephropathy. Diabetes Care 2007; 30 (3): 638-43. (Pubitemid 46354346)
23. Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM. The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008; 2 (7-8): 997-1007.
24. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19 (7): 1283-90.
25. Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20 (9): 2065-74.
26. Ameur RB, Molina L, Bolvin C, Kifagi C, Jarraya F, Ayadi H, et al. Proteomic approaches for discovering bio -markers of diabetic nephropathy. Nephrol Dial Trans plant 2010; 25 (9): 2866-75.
27. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes re search: moving from information to knowledge. Dia betes 2009 Nov; 58 (11): 2429-43.
28. Benito-Martn A, Ucero AC, Santamara B, Lorz C, Kretzler M, Rastaldi MP, et al. Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy. Nefrologia 2009; 29 (1): 13-19.
29. Meikle PJ, Tsorotes D, Barlow CK, Weir J, MacIntosh GL, Barber M, et al. Plasma lipidomic analysis for prediction of unstable coronary artery disease. [Abstract] Circu -lation 2010; 122: A15009.
30. Shi Y. Emerging roles of cardiolipin remodeling in mito -chondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. Journal of Biomedical Research 2010; 24 (1): 6-15.
31. Sorensen CM, Ding J, Zhang Q, Alquier T, Zhao R, Mueller PW, Smith RD, Metz TO. Perturbations in the lipid profile of individuals with newly diagnosed type 1 diabetes mellitus: lipidomics analysis of a Diabetes Antibody Standardization Program sample subset. Clin Biochem 2010; 43 (12): 948-56.
32. Priego-Capote F, Scherl A, Müller M, Waridel P, Lisacek F, Sanchez JC. Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma. Mol Cell Proteomics 2010; 9 (3): 579-92.
33. Hofer SE, Bennetts B, Chan AK, Holloway B, Karschi m -kus C, Jenkins AJ, et al. Association between PON 1 poly morphisms, PON activity and diabetes compli cations. J Diabetes Complications 2006 Sep-Oct; 20 (5): 322-8. (Pubitemid 44292534)
34. Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 dia -betic retinopathy. Mol Vis 2006; 12: 336-41.
35. Kazemi Arababadi M. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis 2010 Oct; 4 (4): 302-6.
36. Balasubbu S, Sundaresan P, Rajendran A, Ramasamy K, Govindarajan G, Perumalsamy N, et al. Association ana -lysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med Genet 2010; 10 (11): 158.
37. Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S, Bellili N, et al; DIABHYCAR and SURDIAGENE Study Groups. Association of ADIPOQ genetic variants and plas ma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant 2010 Jul; 25 (7): 2231-7.
38. Jiang YD, Chang YC, Chiu YF, Chang TJ, Li HY, Lin WH, et al. SLC2A10 genetic polymorphism predicts develop -ment of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes. BMC Med Genet 2010; 11: 126.
39. Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA 2010; 304 (8): 881-9.
40. Yang Y, Andresen BT, Yang K, Zhang Y, Li X, Li X, et al. Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp Biol Med (Maywood) 2010; 235 (10): 1204-11.
41. Stankov K. Genetic predisposition for type 1 diabetes mellitus - The role of endoplasmic reticulum stress in human disease etiopathogenesis. Journal of Biomedical Biochemistry 2010; 29: 139-149.
42. Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011 Feb 9;10(1):16.
43. Hamet P, Tremblay J. Will ADVANCE population genomic determinants improve upon biomarkers in predicting vascular complications of diabetes? Medicographia 2009; 31: 307-13.
44. Golubnitschaja O. Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA Journal 2010; 1: 3-12.
45. Malandrino N, Smith RJ. Personalized medicine in dia -betes. Clin Chem 2011 Feb; 57 (2): 231-40.
46. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33 (Suppl): S11- 61.
47. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, M, Kirkman S, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. DRAFT November 2010 Version. NACB: Laboratory Medicine Practice Guidelines (LMPG) http://www.aacc.org/members/nacb/lmpg/pages/ default.aspx (Accessed: 2010).
48. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Alan C, et al. National Evidence Based Guideline for Diag nosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes. Diabetes Australia and the NHMRC, Canberra 2009.
49. Riaz S, Alam SS, Srai SK, Skinner V, Riaz A, Akhtar MW. Proteomic identification of human urinary biomarkers in diabetes mellitus type 2. Diabetes Technol Ther 2010 Dec; 12 (12): 979-88.
50. DPK Ng. Human Genetics of Diabetic Retinopathy: Cur -rent Perspectives. Journal of Ophthalmology 2010: 1-6.
51. Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia (2011) 54: 803-11.
52. Araki E, Nishikawa T. Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Invest 2010; 1 (3): 90-6.
53. Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010; 33 (12): 2561-6.
54. Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. Hypertens 1998; 16: 2019-26. (Pubitemid 29002383)
55. Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, Kohri K, et al. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes. Diabet Med 2006; 23: 617-22. (Pubitemid 43830061)
56. Van der Zijl NJ, Hanemaaijer R, Tushuizen ME, Schindhelm RK, Boerop J, Rustemeijer C, et al. Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy? Clin Biochem 2010; 43 (7-8): 635-9.
57. Oh JY. Serum cystatin C as a biomarker for predicting coronary artery disease in diabetes. Korean Diabetes J 2010; 34 (2): 84-5.
58. True MW. Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. J Diabetes Sci Technol 2009; 3 (4): 743-7.
59. Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, Klyne R, et al. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 2010; 33 (2): 252-7.
60. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32 (2): 91-8.
61. Gul K, Nas S, Ozdemir D, Gumus M, Ersoy R, Cakir B. CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and micro -vascular complications. Am J Med Sci 2011;341 (1): 28-32.
62. Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional Markers of Gly cemia: Associations with microvascular conditions. Dia betes Care [Abstract]. 2011. doi: 10.2337/dc10-1945.